Please login to the form below

Not currently logged in
Email:
Password:

Takeda will acquire Nycomed, reports say

Takeda Pharmaceutical Company has agreed to buy Swiss drugmaker Nycomed in a deal worth around 1trn yen ($12bn), according to a report in Japanese newspaper, Nikkei

Takeda Pharmaceutical Company has agreed to buy Swiss drugmaker Nycomed in a deal worth around 1trn yen ($12bn), according to a report in Japanese newspaper, Nikkei.

The report follows denials by Takeda, the largest pharma company in Japan, earlier this month: "Takeda has not agreed to any such agreement as suggested by certain newspaper publications… Takeda is constantly seeking and evaluating opportunities to increase shareholder value and enhance our business through strategic investment, however, there is nothing that needs to be announced at this point."

Initial media reports had alleged that the deal was in its final stages, while another said that Takeda is talking to banks about financing the deal.

Rumours of the deal came just days after Nycomed entered into a co-branding agreement with Almirall to commercialise roflumilast in Spain. Romflumilast is a once-daily tablet for patients with COPD. It is an orally administered phosphodiesterase 4 (PED4) enzyme inhibitor and the first oral anti-inflammatory treatment for COPD.

Related stories
Takeda denies Nycomed takeover talks
Almirall/Nycomed COPD co-branding deal

18th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics